Cantor Fitzgerald Weighs in on Zai Lab FY2025 Earnings

Zai Lab Limited (NASDAQ:ZLAB) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Zai Lab in a report released on Tuesday, March 4th. Cantor Fitzgerald analyst L. Watsek forecasts that the company will earn ($1.38) per share for the year. Cantor Fitzgerald has a “Strong-Buy” rating on the stock. The consensus estimate for Zai Lab’s current full-year earnings is ($2.58) per share.

Separately, Bank of America reiterated a “neutral” rating and issued a $36.10 target price (up from $29.00) on shares of Zai Lab in a research report on Monday.

Zai Lab Stock Performance

NASDAQ:ZLAB opened at $35.91 on Thursday. The company has a fifty day moving average of $28.10 and a two-hundred day moving average of $26.25. The stock has a market capitalization of $3.93 billion, a PE ratio of -12.96 and a beta of 1.02. Zai Lab has a fifty-two week low of $13.48 and a fifty-two week high of $36.60.

Zai Lab (NASDAQ:ZLAB) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.19). Zai Lab had a negative return on equity of 36.97% and a negative net margin of 76.14%. The firm had revenue of $109.07 million for the quarter, compared to analysts’ expectations of $110.15 million.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. GF Fund Management CO. LTD. purchased a new position in shares of Zai Lab in the fourth quarter valued at approximately $29,000. Public Employees Retirement System of Ohio lifted its stake in Zai Lab by 20.8% in the fourth quarter. Public Employees Retirement System of Ohio now owns 18,480 shares of the company’s stock worth $484,000 after acquiring an additional 3,179 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Zai Lab by 2.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 57,114 shares of the company’s stock worth $1,496,000 after acquiring an additional 1,200 shares during the last quarter. Woodline Partners LP lifted its stake in Zai Lab by 9.4% in the fourth quarter. Woodline Partners LP now owns 1,759,797 shares of the company’s stock worth $46,089,000 after acquiring an additional 151,835 shares during the last quarter. Finally, Vestal Point Capital LP acquired a new stake in Zai Lab during the fourth quarter worth approximately $7,857,000. Hedge funds and other institutional investors own 41.65% of the company’s stock.

Insider Buying and Selling

In other Zai Lab news, insider Rafael Amado sold 7,583 shares of the stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $26.28, for a total transaction of $199,281.24. Following the completion of the transaction, the insider now owns 33,834 shares of the company’s stock, valued at $889,157.52. This trade represents a 18.31 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Ying Du sold 50,000 shares of the firm’s stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of $34.47, for a total transaction of $1,723,500.00. Following the completion of the transaction, the chief executive officer now directly owns 494,117 shares of the company’s stock, valued at approximately $17,032,212.99. The trade was a 9.19 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 122,127 shares of company stock worth $4,024,442. Insiders own 13.88% of the company’s stock.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.